United States Patent 8,617,543: What the Claims Actually Cover, and Where the Landscape Squeezes Them
United States Patent 8,617,543 claims a topical or injectable method that reduces adipose tissue, lipomas, or scars using a specific modified Clostridium histolyticum collagenase ColH (“ColH-FM”) or a peptide containing its sequence. The modification is constrained to two structural elements: (i) a single substitution corresponding to Glu451Asp in wild-type ColH, and (ii) an N-terminal peptide motif “CKGGRAKDC-G(x)” where x = 2 to 6, tied to SEQ ID NO: 2. Independent coverage is method-of-treatment; dependent claims broaden route (inject/topical), and add topical delivery via transdermal delivery systems and specified excipients (saline, aqueous dextran, aqueous hetastarch).
This claim architecture is narrow at the molecule level (two precise modifications) but broad at the therapeutic-use level (adipose tissue, lipomas, scars; “selected locations” plus injection or topical). The enforceability hinges on whether an accused product uses that same modified collagenase architecture and whether the use aligns with the claimed indications.
1) What does US 8,617,543 claim, in operational terms?
Core claimed method
Claims 1 to 3 cover administering an effective amount of either:
- (a) the modified single mutant collagenase ColH-FM, or
- (b) a peptide that includes the sequence of ColH-FM,
to:
- reduce adipose tissue at selected body locations (Claim 1),
- reduce or remove lipomas (Claim 2),
- reduce scars (Claim 3),
in a subject “in need of” those outcomes.
Molecule constraints (the real gatekeeper)
Every independent use claim (1-3) requires that ColH-FM is:
1) A Clostridium histolyticum collagenase ColH with a single substitution corresponding to Glu451Asp of wild-type ColH.
2) An N-terminal peptide motif: CKGGRAKDC-G(x) at the N-terminus of the ColH sequence, where x is 2 to 6 (SEQ ID NO: 2).
Claim 10 further ties the full protein sequence to SEQ ID NO: 1.
Route and formulation
Dependent claims add how it is delivered:
- Injected or topically applied (Claim 4 for adipose; Claim 5 for scars).
- Topical using a transdermal delivery system in cream/serum/liquid (Claim 6 for Claim 4; Claim 7 for Claim 5).
- Pharmaceutical composition with pharmaceutically acceptable carrier (Claim 8).
- Carrier exemplars: saline, aqueous dextran, aqueous hetastarch (Claim 9, and mirrored in Claims 12 and 15).
Claim structure summary
| Claim set |
Therapeutic objective |
Delivery options |
Molecule gate (must match) |
| Claims 1-3 (independent) |
adipose reduction; lipoma reduction/removal; scar reduction |
admin to subject |
ColH-FM with Glu451Asp + CKGGRAKDC-G(x), x=2-6 at N-terminus |
| Claims 4-7 (dependent) |
adipose and scars |
inject or topical; topical via transdermal delivery system; cream/serum/liquid |
same ColH-FM motif and substitution |
| Claims 8-16 (dependent) |
all above (through dependent chain) |
pharmaceutical composition |
carrier includes saline/dextran/hetastarch; sequence defined (SEQ ID NO: 1) |
2) How strong are these claims as enforceable scope?
Strength: explicit structural definition
The molecule is defined with two tight constraints:
- single-point substitution (Glu451Asp)
- specific N-terminal motif with variable length constraint (CKGGRAKDC-G(x), x=2 to 6)
That design reduces the risk that “similar collagenases” fall inside the claim unless they use the same engineered architecture. For enforcement, that is a plus: claim boundaries are definable by sequence and engineered position.
Weakness: “peptide that includes the sequence of ColH-FM” can broaden mode-of-infringement
The method allows administration of “a peptide that includes the sequence of ColH-FM.” That phrasing can capture:
- fragments,
- fusion constructs,
- partial sequences,
so long as they include the ColH-FM sequence. The key litigation lever becomes claim construction: whether “includes the sequence” means the whole ColH-FM sequence or any fragment that contains elements. If construed broadly, it increases infringement pathways.
Weakness: therapeutic breadth across different tissue types
Adipose, lipomas, and scars are different clinical targets. Competitors might argue that pre-existing collagenase uses for dermal or soft tissue are known, while still avoiding the required engineered molecule. But the broader the medical objective range, the more likely the patent will face validity challenges based on overlapping prior art activity, even if molecule structure is novel.
Route breadth helps operators but may also raise obviousness risk
Claims cover:
- injection,
- topical,
- transdermal delivery formulations (cream/serum/liquid),
- specific carriers.
Route/formulation that is already conventional increases the probability that an examiner (or challenger) could argue obviousness once the molecule is identified as a known collagenase platform. Here, the molecule is the differentiator; route is the residual risk factor.
3) What prior-art pressure is likely to hit this landscape?
This patent sits in a crowded area where the general concept of collagenase-based tissue remodeling exists. The legal problem is not “collagenase for tissue” being new. The legal problem is whether the particular engineered collagenase (Glu451Asp + CKGGRAKDC-G(x) N-terminal motif) would have been obvious in view of what was already available.
High-risk prior art categories
Without reproducing unsupported specifics, the landscape pressure logically concentrates in these zones:
1) Clostridium histolyticum collagenase engineering
Prior patents and publications that disclose modifying ColH for altered activity, selectivity, or delivery. Even if the exact motif differs, challengers typically argue that the modification is an expected optimization step.
2) N-terminal targeting motifs and delivery peptides
If N-terminal peptide motifs (including cysteine-rich motifs or sequences with established biological uptake/delivery behavior) appear in adjacent protein engineering disclosures, challengers can argue that appending or transplanting such motifs onto proteins is an obvious choice.
3) Topical/transdermal formulation conventions
Cream/serum/liquid transdermal delivery is a standard drug delivery bucket. Claims that list carriers like saline, dextran, and hetastarch are common in formulation disclosures; those ingredients are rarely a novelty driver.
4) Use in adipose/lipoma/scar indications with related enzymes
Even if collagenase itself is not used identically, adjacent enzymatic approaches to scars and soft tissue remodeling often exist. For obviousness, challengers can combine:
- known therapeutic rationale for tissue collagen modification
- known enzyme platform
- known delivery methods
Where the patent likely holds up
The fixed structural requirements (SEQ ID NO: 1; specific N-terminal motif with x=2–6; Glu451Asp) make it harder for a challenger to assert anticipation unless an earlier disclosure matches that exact construct or an equivalent with all required features.
4) Where competitors can design around this patent (practical freedom points)
Because the claim gate is structural, the most direct design-around routes are to change at least one required element:
Molecule-level carve-outs
- Use a ColH variant without the Glu451Asp substitution (change the single amino acid).
- Remove or replace the N-terminal motif structure (break CKGGRAKDC-G(x) or change the x-range beyond 2 to 6).
- Use a different collagenase from the same organism but with different motif and substitution combination.
Sequence-fragment ambiguity
If a competitor uses a peptide/protein that is not “including the sequence of ColH-FM” under the claim construction standard, they can reduce risk. This turns on claim interpretation and technical sequence matching.
Formulation and route
Claims do not restrict carriers beyond examples, but they do constrain the explicit carrier lists in dependent claims. A competitor can still pick different carriers and argue non-infringement of dependent claim coverage, while leaving independent method claims as the remaining risk.
Indication and outcome framing
Even if a competitor treats soft tissue, the legal risk increases if the marketing or study outcome is framed as:
- reducing adipose tissue at selected locations,
- reducing or removing lipomas,
- reducing scars.
A competitor can reduce exposure by targeting different endpoints that fall outside the specific language, although “in need of reducing” language can be broad depending on claim construction.
5) Competitive and investment implications: how to treat this patent in diligence
If you license or invest, the diligence focus is not “collagenase,” it is “identity of the construct.”
The enforceability question is sequence-level:
- Does the candidate product contain the exact engineered ColH-FM architecture described in the claims?
- Does it include the N-terminal motif with x in 2–6?
- Does it carry Glu451Asp as the single substitution corresponding to that position?
- Does it match SEQ ID NO: 1?
Freedom to operate (FTO) is asymmetric
- A product that uses a standard collagenase or a different engineered collagenase is likely outside the literal claim.
- A product that uses the exact engineered construct is exposed on method-of-treatment, route, and transdermal formulation strategies.
The patent’s value profile
The patent’s value is tied to a narrow molecular signature but a broad tissue-use footprint. That combination usually improves its bargaining position with parties who already adopted the same engineered construct.
Key Takeaways
- US 8,617,543 claims a method-of-treatment using a precisely defined engineered ColH: Glu451Asp plus N-terminal motif CKGGRAKDC-G(x), x=2-6, with protein identity tied to SEQ ID NO: 1 and motif defined by SEQ ID NO: 2.
- Therapeutic scope covers adipose reduction, lipoma reduction/removal, and scar reduction, with delivery broadened to injection and topical transdermal systems (cream/serum/liquid) and composition carriers including saline, dextran, and hetastarch via dependent claims.
- The strongest enforceability lever is sequence/construct matching; the most straightforward design-arounds change the single substitution and/or the N-terminal motif structure or x-range.
- Validity risk and prior-art pressure likely concentrate on collagenase engineering, peptide motif transplant concepts, and standard topical/transdermal delivery practices, while the novelty hinge remains the exact engineered combination required by the claims.
FAQs
1) Does the patent cover all collagenases for fat or scars?
No. It is limited to a modified single mutant ColH with the required Glu451Asp substitution and CKGGRAKDC-G(x) N-terminal motif (x=2–6), or peptides including the ColH-FM sequence.
2) Can a competitor avoid infringement by changing formulation but keeping the same enzyme?
Changing carriers can help at the dependent-claim level (those carrier examples are in dependent claims), but it does not avoid infringement of the independent method if the accused product still administers the required ColH-FM construct for the claimed indications.
3) Is topical application automatically included?
Topical is included through dependent claims (inject or topically applied). Transdermal delivery systems in cream/serum/liquid are specified in dependent claims, so topical-only without the transdermal system framing could change claim coverage depending on construction.
4) What is the most sensitive variable for infringement risk?
Whether the product uses the exact engineered ColH-FM defined by the claims. Sequence matching for the single substitution and N-terminal motif is the practical determinant.
5) What does “peptide that includes the sequence of ColH-FM” imply for design-around?
It creates an additional infringement pathway beyond administering the full protein. A competitor should treat this as a risk for any construct that contains the claimed ColH-FM sequence, not just the full-length enzyme.
References
[1] United States Patent 8,617,543. Claims (Claims 1-16).
